Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene.
China's Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive sta
UK researchers say they have developed an algorithm that is more accurate than current tools at predicting an individual’s risk of developing cardiovascular disease in the
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.